Topic: demethylases

​Alzheimer’s Disease (AD) is a progressive brain disorder known to be the most common type of dementia in aging population, yet therapeutical curative approaches remain unmet. Epigenetics is one of the many factors that contribute to the development of the disease, and it is considered a potential therapeutical target on the search of novel pharmacological drugs. Particularly, N6-methyladenosine (m6A) RNA methylation has been shown to be one of the main dynamically reversible epigenetic modifications contributing to the progression of neural degeneration. This way, abnormal levels of m6A have

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and the accumulation of abnormal proteins, such as beta-amyloid plaques, in the brain. Epitranscriptomics, a branch of molecular biology, studies chemical modifications to RNA molecules and their impact on gene expression and cellular function. Among these modifications, N6-methyladenosine (m6A) plays crucial roles in various aspects of RNA metabolism, including RNA splicing, stability, translation, and localization. Dysregulation of m6A modification has been implicated in the development an